Association between the PAI-1 4G/5G Gene Polymorphism and the Risk of Systemic Lupus Erythematosus/Lupus Nephritis.
Plasminogen activator inhibitor type 1 (PAI-1) correlates with the risk and progression of systemic lupus erythematosus (SLE). We aimed to assess the relationship between the PAI-1 4G/5G gene polymorphism and SLE/lupus nephritis risk. We identified the eligible studies regarding the association between the PAI-1 4G/5G gene polymorphism and the risk of SLE/lupus nephritis. The odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using a fixed-effects model or, in the presence of heterogeneity, a random-effects model. A total of six studies were enrolled in our pooled analysis. The PAI-1 4G/5G gene polymorphism had no significant association with the risk of SLE among overall populations, Asians and Caucasians. Nor was it associated with susceptibility to lupus nephritis among overall populations, Asians and Caucasians. Sensitivity analysis yielded similar results. No marked publication bias was noted. In conclusion, the PAI-1 4G/5G gene polymorphism is not associated with susceptibility to SLE/lupus nephritis among overall populations, Asians and Caucasians. However, more studies should be conducted in the future.